We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.
BLCM

Delisted

BLCM was delisted on the 1st of June, 2023.

Back to rankings

80 hedge funds and large institutions have $266M invested in Bellicum Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 7

21% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 24

14% more funds holding

Funds holding: 70 → 80 (+10)

5% less call options, than puts

Call options by funds: $622K | Put options by funds: $656K

28% less capital invested

Capital invested by funds: $370M → $266M (-$103M)

Holders
80
Holders Change
+10
Holders Change %
+14.29%
% of All Funds
2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
29
Reduced
24
Closed
7
Calls
$622K
Puts
$656K
Net Calls
-$34K
Net Calls Change
+$394K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$4.44M
2
KCM
Kennedy Capital Management
Missouri
+$3.84M
3
Ameriprise
Ameriprise
Minnesota
+$2.64M
4
BIT
BlackRock Institutional Trust
California
+$2.08M
5
BFA
BlackRock Fund Advisors
California
+$1.99M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.34M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.94M
3
Zurich Cantonal Bank
Zurich Cantonal Bank
Switzerland
-$1.55M
4
First Eagle Investment Management
First Eagle Investment Management
New York
-$1.4M
5
QF
QVT Financial
New York
-$904K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$998K +$1.3M +7,325 New
Charles Schwab
27
Charles Schwab
California
$948K +$65.5K +369 +6%
Creative Planning
28
Creative Planning
Kansas
$941K +$689K +3,880 +128%
Deutsche Bank
29
Deutsche Bank
Germany
$886K +$13.5K +76 +1%
TCM
30
Tekla Capital Management
Massachusetts
$817K – – –
TCIM
31
TIAA CREF Investment Management
New York
$811K -$118K -666 -10%
VIA
32
Vident Investment Advisory
Georgia
$642K -$108K -607 -11%
FAM
33
Fred Alger Management
New York
$640K -$53.3K -300 -6%
HCM
34
Highbridge Capital Management
New York
$609K +$794K +4,472 New
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$589K -$19.5K -110 -2%
Millennium Management
36
Millennium Management
New York
$581K +$757K +4,263 New
Wells Fargo
37
Wells Fargo
California
$543K +$503K +2,831 +246%
CS
38
Credit Suisse
Switzerland
$518K +$193K +1,085 +40%
DADC
39
D.A. Davidson & Co
Montana
$491K +$640K +3,605 New
TA
40
Teachers Advisors
New York
$485K +$32.8K +185 +5%
WA
41
Wasatch Advisors
Utah
$416K – – –
Swiss National Bank
42
Swiss National Bank
Switzerland
$399K – – –
Goldman Sachs
43
Goldman Sachs
New York
$392K +$291K +1,638 +132%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$389K -$51.5K -290 -9%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$311K +$59.8K +337 +17%
Allianz Asset Management
46
Allianz Asset Management
Germany
$297K +$388K +2,184 New
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$291K – – –
ProShare Advisors
48
ProShare Advisors
Maryland
$290K +$38.3K +216 +11%
AllianceBernstein
49
AllianceBernstein
Tennessee
$264K – – –
Zurich Cantonal Bank
50
Zurich Cantonal Bank
Switzerland
$245K -$1.55M -8,717 -83%
1
2
3 4

BLCM Hedge Fund Activity: Q4 2016 in Review

80 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2016, worth a combined $266M — down 28% from $370M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BLCM positions and 7 closed out — a net gain of 10 holders — while 29 added to existing stakes and 24 trimmed.

The largest buyer was Eventide Asset Management, opening a new position worth an estimated $4.44M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.34M.

  • 80 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2016, up from 70 in Q3 2016.
  • Funds reported $266M of Bellicum Pharmaceuticals, Inc. stock for Q4 2016, down 28% quarter-over-quarter.
  • 17 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2016 and 7 closed out, a net change of +10 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2016 was Eventide Asset Management, an estimated $4.44M added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2016 was T. Rowe Price Associates, an estimated $3.34M sold.

Based on aggregated 13F filings for Q4 2016.